Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.…
Immunome to Present at Upcoming Investor Conferences
Immunome (NASDAQ: IMNM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 267 employees.
The shares were at 15.69 USD on 20 November 2026, up 3.0% over 52 weeks. Its 52-week range is 15.46 USD to 30.06 USD: the price is 47.8% below the high and 1.5% above the low.
Its market capitalisation is 1.85B USD.
Immunome reports return on equity of -33.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 450.20M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 35.13 USD is 123.9% above the current price. The next earnings report is expected on 3 March 2027.